Researchers in Australia have led a first-in-human trial for a breakthrough gene-editing therapy that halves bad cholesterol ...

A statin isn’t the only answer anymore to lowering cholesterol. The lipid-reducing medicines, among the most widely prescribed drugs in the U.S., have been a mainstay of heart-disease prevention and ...

The convergence of AI, quantum computing, and biosciences is propelling the global healthcare industry into a new era - now projected to surpass US$1.7 trillion in AI-driven biotech spending by 2025, ...

Researchers have developed a synthetic regeneration system for genetically editing crops, avoiding the challenging step of ...

Kala Bio has secured a $375,000 convertible loan from an investor to negotiate more funding and avoid foreclosure by Oxford ...

ERS Genomics Limited ('ERS'), the CRISPR licensing company, and Dyadic Applied BioSolutions ('Dyadic'), a global ...

At American Heart Association conference in New Orleans, Crispr Therapeutics CRSP said a single dose of its gene-editing drug ...

The company scans entire proteins with CRISPR to find functional vulnerabilities, then hunts for molecules that exploit them ...

Choose Boston Business Journal as a preferred news source to see more of our reporting on Google. The deal could mean over ...

Adherence to cholesterol-lowering treatments remains one of the biggest challenges in preventing heart disease. The one-time ...

ERS Genomics Limited (‘ERS’), the CRISPR licensing company, and Dyadic Applied BioSolutions, a global biotechnology company ...

ERS Genomics Limited ('ERS'), the CRISPR licensing company, and Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered ...